<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03133546</url>
  </required_header>
  <id_info>
    <org_study_id>ETOP 10-16</org_study_id>
    <secondary_id>2016-002029-12</secondary_id>
    <secondary_id>ESR-15-11666</secondary_id>
    <secondary_id>MO39447</secondary_id>
    <nct_id>NCT03133546</nct_id>
  </id_info>
  <brief_title>Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M (BOOSTER)</brief_title>
  <acronym>BOOSTER</acronym>
  <official_title>A Randomised Phase II Trial of Osimertinib and Bevacizumab Versus Osimertinib Alone as Second-line Treatment in Stage IIIb-IVb NSCLC With Confirmed EGFRm and T790M</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European Thoracic Oncology Platform</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>European Thoracic Oncology Platform</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      BOOSTER is a randomised, controlled, phase II trial comparing osimertinib and bevacizumab
      versus osimertinib alone as second-line treatment in patients with stage IIIb-IVb non-small
      cell lung carcinoma (NSCLC) harbouring activating EGFR (exon 19 deletion or L858R) and T790M
      resistance mutation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Lung cancer has been the most common carcinoma in the world for several decades. Non-small
      cell lung carcinoma (NSCLC) represents approximately 80-85% of all lung cancers. At the time
      of diagnosis approximately 70% of NSCLC patients already have advanced or metastatic disease
      not amenable to surgical resection. A significant percentage of early stage NSCLC patients
      who have undergone surgery subsequently develop distant recurrence.

      First-generation EGFR tyrosine kinase inhibitors (TKIs) provide significant clinical benefit
      in patients with advanced EGFR-mutant (EGFRm) non-small cell lung carcinoma (NSCLC). However,
      all patients ultimately develop disease progression, driven - as the most prevalent
      identified biological mechanism - by the acquisition of a second T790M EGFR TKI resistance
      mutation.

      Osimertinib (AZD9291) is a novel oral, potent, and selective third-generation irreversible
      inhibitor of both EGFRm-sensitizing and T790M resistance mutants. This
      mono-anilino-pyrimidine compound is structurally distinct from other third-generation EGFR
      TKIs and offers a pharmacologically differentiated profile from earlier first and second
      generation EGFR TKIs.

      Osimertinib is being evaluated in several prospective clinical trials, notably in frontline
      treatment, in the adjuvant setting, and in combination with later lines in EGFRm positive
      advanced disease. Combination treatments that target both tumour cells and tumour
      microenvironment (such as angiogenesis) may be a promising strategy for further improving
      efficacy outcomes in patients with EGFRm NSCLC following progression on EGFR TKI therapy and
      other lines of therapy. There is thus a considerable unmet clinical need for novel
      therapeutic options that can further extend the efficacy of targeted agents such as EGFR
      TKIs, across all lines of therapy.

      Bevacizumab is a recombinant humanized monoclonal IgG1 antibody that binds to and inhibits
      the interaction of VEGF-A to its receptors (Flt-1 and KDR) on the surface of endothelial
      cells. The interaction of VEGF with its receptors leads to endothelial cell proliferation and
      new blood vessel formation in in vitro models of angiogenesis. Neutralising the biological
      activity of VEGF regresses the vascularisation of tumours, normalises remaining tumour
      vasculature, and inhibits the formation of new tumour vasculature, thereby inhibiting tumour
      growth. Bevacizumab is indicated for the first-line treatment of unresectable, locally
      advanced, recurrent or metastatic non-squamous NSCLC in combination with carboplatin and
      paclitaxel.

      Osimertinib monotherapy, at the dose to be evaluated in this trial, has shown consistent and
      high objective response rates in the target patient population.

      Anti-angiogenic agents targeting the VEGF/VEGFR signalling pathway have been shown to provide
      additional efficacy when used in combination with first-line platinum-based chemotherapy in
      several trials in non-squamous NSCLC or in combination with erlotinib as first line therapy
      in EGFRm positive NSCLC patients. The combination of osimertinib plus an anti-angiogenic
      agent such as bevacizumab may provide a wider activity against tumours that have developed
      resistance to EGFR TKI agents by blocking the dual pathways of proliferative signalling and
      antigenic signalling. Preclinical studies suggested that patients on lower doses of EGFR TKI
      tend to develop treatment resistance earlier than those who receive higher doses. Therefore
      the combination may also delay the development of subsequent resistance as the preclinical
      studies suggested anti-angiogenic agents may increase intratumoural uptake of anti-cancer
      drugs by changing tumour vessel physiology.

      Efficacy and safety data from the osimertinib monotherapy studies have shown promising
      efficacy and an acceptable safety profile at the recommended dose of 80 mg once daily. The
      combination of osimertinib with bevacizumab may have the potential to provide additional
      clinical benefit in terms of increased and/or prolonged disease control and a delay in the
      emergence of resistance in patients with advanced EGFRm NSCLC who have progressed following a
      prior EGFR TKI agent, compared against the current standard of care (chemotherapy or another
      EGFR TKI) or monotherapy of any of the individual agents.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 31, 2017</start_date>
  <completion_date type="Anticipated">May 2022</completion_date>
  <primary_completion_date type="Anticipated">May 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival (PFS)</measure>
    <time_frame>PFS will be measured from date of patient enrolment until documented progression, or death, if progression is not documented, evaluated up to 48 months from enrolment of the first patient and compared between treatment arms.</time_frame>
    <description>PFS in patients with locally advanced or metastatic NSCLC will be assessed according to RECIST 1.1 criteria.The two treatment arms will be compared using the Kaplan-Meier method.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate (ORR)</measure>
    <time_frame>ORR will be evaluated from date of patient enrolment until termination of trial treatment across all assessment timepoints, evaluated up to 48 months from enrolment of the first patient and compared between treatment arms.</time_frame>
    <description>ORR, defined as the percentage of patients reaching a complete or partial response, based on evaluation using RECIST 1.1 criteria and disease control rate.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control</measure>
    <time_frame>Evaluated across all assessment timepoints from date of patient enrolment to termination of trial treatment, evaluated up to 48 months from enrolment of the first patient and compared between treatment arms.</time_frame>
    <description>Disease control, defined as complete or partial response, or disease stabilisation confirmed at subsequent radiological assessment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>From date of signature of informed consent until 30 days after all trial treatment discontinuation, for a maximum of 48 months from enrolment of the first patient</time_frame>
    <description>Adverse events, graded by CTCAE 4.0, will be recorded from date of signature of informed consent until 30 days after all trial treatment discontinuation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>Evaluated from date of enrolment until death from any cause, assessed at 48 months from enrolment of the first patient.</time_frame>
    <description>Defined as the time from date of randomisation until death from any cause.</description>
  </secondary_outcome>
  <other_outcome>
    <measure>T790M evolution in tissue and plasma/serum between baseline and disease progression on trial treatment</measure>
    <time_frame>Assessed at baseline and disease progression on trial treatment (maximum 48 months)</time_frame>
    <description>For this correlative studie tumour tissue blocks, plasma and serum samples will be collected at trial entry and at disease progression on trial treatment.</description>
  </other_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">154</enrollment>
  <condition>Non Small Cell Lung Cancer Metastatic</condition>
  <arm_group>
    <arm_group_label>Osimertinib plus Bevacizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive treatment with osimertinib and bevacizumab until disease progression, lack of tolerability or the patient declines further treatment. Treatment may also continue beyond progression for as long as the patient may still derive benefit.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Osimertinib alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive treatment with osimertinib until disease progression, lack of tolerability or the patient declines further treatment. Treatment may also continue beyond progression for as long as the patient may still derive benefit.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Osimertinib</intervention_name>
    <description>Osimertinib is administered orally at 80mg once daily. Doses should be taken approximately 24 hours apart at the same time point each day. The appropriate number of osimertinib tablets will be provided to patients to be self-administered at home. AstraZeneca will supply osimertinib as tablets for oral administration.
AstraZeneca will supply osimertinib as tablets for oral administration.</description>
    <arm_group_label>Osimertinib plus Bevacizumab</arm_group_label>
    <arm_group_label>Osimertinib alone</arm_group_label>
    <other_name>Tagrisso</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bevacizumab</intervention_name>
    <description>Bevacizumab is administered at 15mg/kg intravenously on day 1 of every 3-week cycle. Bevacizumab for intravenous administration will be supplied by Roche.</description>
    <arm_group_label>Osimertinib plus Bevacizumab</arm_group_label>
    <other_name>Avastin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients (male/female) must be &gt;18 years of age.

          -  Patients diagnosed with NSCLC, stage IIIb/IIIc (not amenable to radical therapy) or
             IVa/IVb according to 8th TNM classification, after progression following prior EGFR
             TKI therapy (erlotinib, gefitinib, dacomitinib or afatinib) as the most recent
             treatment regimen;

          -  Pathological diagnosis of predominantly non-squamous NSCLC;

          -  Maximum one line of previous platinum based chemotherapy;

          -  Histological or cytological confirmation of EGFRm (exon 19 deletion or exon 21L858R);

          -  Locally confirmed T790M mutation determined from biopsy (preferred) or on circulating
             tumour DNA, documented in tissue, plasma or serum after disease progression on the
             most recent treatment regimen;

          -  Plasma, serum, and tumour (preferred) tissue or cytology (if biopsy was taken and FFPE
             tumor material is not yet fully depleted) after disease progression on the most recent
             EGFR TKI treatment available for central confirmation of T790M;

          -  Measurable or evaluable disease according to RECIST 1.1;

          -  Adequate haematological, renal and liver function;

          -  World Health Organization (WHO) performance status 0-2.

        Exclusion Criteria:

          -  Patients with mixed NSCLC with predominantly squamous cell cancer, or with any small
             cell lung cancer (SCLC) component;

          -  Symptomatic or active central nervous system metastases, as indicated by progressive
             growth or increasing need of steroids.

          -  Patients currently receiving medications or herbal supplements known to be potent
             CYP3A4 inducers;

          -  Patients with any unresolved toxicities from prior therapy greater than CTCAE V 4.0
             grade 1 (exception: alopecia &amp; grade 2, prior platinuma-therapy related neuropathy)

          -  Previous treatment with osimertinib and/or bevacizumab;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Solange Peters, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Centre Hospitalier Universitaire Vaudois</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Rolf Stahel, MD</last_name>
    <role>Study Chair</role>
    <affiliation>University Hospital Zuerich, Zurich, Switzerland</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Barbara Ruepp, PharmD</last_name>
    <phone>+41315119416</phone>
    <email>regulatoryoffice@etop-eu.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>St. James Hospital</name>
      <address>
        <city>Dublin</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sinead Cuffe, MD</last_name>
      <email>SCuffe@stjames.ie</email>
    </contact>
    <investigator>
      <last_name>Sinead Cuffe, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mid Western Cancer Centre</name>
      <address>
        <city>Limerick</city>
        <country>Ireland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Linda Coate, MD</last_name>
      <email>lindae.coate@hse.ie</email>
    </contact>
    <investigator>
      <last_name>Linda Coate, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Centre</name>
      <address>
        <city>Goyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ji-Youn Han, MD</last_name>
      <email>jymama@ncc.re.kr</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Byong C Cho, MD</last_name>
      <email>cbc1971@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Byong C C, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>VU University Medical Centre</name>
      <address>
        <city>Amsterdam</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Sayed Hashemi, MD</last_name>
      <email>s.hashemi@vumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National University Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ross Soo, MD</last_name>
      <email>ross_soo@nuhs.edu.sg</email>
    </contact>
    <investigator>
      <last_name>Ross Soo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Tan Tock Seng Hospital</name>
      <address>
        <city>Singapore</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Siew W Wong, MD</last_name>
      <email>siewwei@imc.jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Siew W Wong, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital General Alicante</name>
      <address>
        <city>Alicante</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bartomeu Massuti, MD</last_name>
      <email>bmassutis@seom.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Magarita Majem, MD</last_name>
      <email>mmajem@santpau.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICO Badalona</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enric Carcereny, MD</last_name>
      <email>ecarcereny@iconcologia.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ICO Hospitalet</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ernest Nadal, MD</last_name>
      <email>esnadal@iconcologia.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>OSI Bilbao Basurto</name>
      <address>
        <city>Bilbao</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria A Sala, MD</last_name>
      <email>marian.salagonzales@osakidetza.eus</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Teresa Herrara</name>
      <address>
        <city>La Coruna</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rosario Garcia Campelo, MD</last_name>
      <email>MA.Rosario.Garcia.Campelo@sergas.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fund. Jimenez Diaz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manuel Domine, MD</last_name>
      <email>manueldomine@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de la Princesa</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose M Sanchez, MD</last_name>
      <email>jmiguelst@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital la Paz</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Javier de Castro, MD</last_name>
      <email>javier.decastro@salud.madrid.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Puerta de Hierro</name>
      <address>
        <city>Madrid</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mariano Provencio, MD</last_name>
      <email>mprovencio.ensayoclinico@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen del Rocio</name>
      <address>
        <city>Sevilla</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernabe Reyes, MD</last_name>
      <email>reyesbernab@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Arnau de Vilanova</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Garcia, MD</last_name>
      <email>joseche812@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital General de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ana Blasco, MD</last_name>
      <email>blascocordellat@yahoo.es</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre Hospitalier Universitaire Vaudois</name>
      <address>
        <city>Lausanne</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Solange Peters, MD</last_name>
      <phone>+41795560192</phone>
      <email>solange.peters@chuv.ch</email>
    </contact>
    <investigator>
      <last_name>Solange Peters, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital St. Gallen</name>
      <address>
        <city>St. Gallen</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Martin Fruh, MD</last_name>
      <email>martin.frueh@kssg.ch</email>
    </contact>
    <investigator>
      <last_name>Martin Früh, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Kantonsspital Winterthur</name>
      <address>
        <city>Winterthur</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Miklos Pless, MD</last_name>
      <email>miklos.pless@ksw.ch</email>
    </contact>
    <investigator>
      <last_name>Miklos Pless, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>UniversitatSpital Zurich</name>
      <address>
        <city>Zurich</city>
        <country>Switzerland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christian Britschgi, MD</last_name>
      <email>christian.britschgi@usz.ch</email>
    </contact>
    <investigator>
      <last_name>Christian Britschgi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Ireland</country>
    <country>Korea, Republic of</country>
    <country>Netherlands</country>
    <country>Singapore</country>
    <country>Spain</country>
    <country>Switzerland</country>
  </location_countries>
  <reference>
    <citation>Bonomi PD. Implications of key trials in advanced nonsmall cell lung cancer. Cancer. 2010 Mar 1;116(5):1155-64. doi: 10.1002/cncr.24815. Review.</citation>
    <PMID>20087963</PMID>
  </reference>
  <reference>
    <citation>Jackman DM, Miller VA, Cioffredi LA, Yeap BY, Jänne PA, Riely GJ, Ruiz MG, Giaccone G, Sequist LV, Johnson BE. Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials. Clin Cancer Res. 2009 Aug 15;15(16):5267-73. doi: 10.1158/1078-0432.CCR-09-0888. Epub 2009 Aug 11.</citation>
    <PMID>19671843</PMID>
  </reference>
  <reference>
    <citation>Oxnard GR, Arcila ME, Sima CS, Riely GJ, Chmielecki J, Kris MG, Pao W, Ladanyi M, Miller VA. Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res. 2011 Mar 15;17(6):1616-22. doi: 10.1158/1078-0432.CCR-10-2692. Epub 2010 Dec 6.</citation>
    <PMID>21135146</PMID>
  </reference>
  <reference>
    <citation>Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, Palmero R, Garcia-Gomez R, Pallares C, Sanchez JM, Porta R, Cobo M, Garrido P, Longo F, Moran T, Insa A, De Marinis F, Corre R, Bover I, Illiano A, Dansin E, de Castro J, Milella M, Reguart N, Altavilla G, Jimenez U, Provencio M, Moreno MA, Terrasa J, Muñoz-Langa J, Valdivia J, Isla D, Domine M, Molinier O, Mazieres J, Baize N, Garcia-Campelo R, Robinet G, Rodriguez-Abreu D, Lopez-Vivanco G, Gebbia V, Ferrera-Delgado L, Bombaron P, Bernabe R, Bearz A, Artal A, Cortesi E, Rolfo C, Sanchez-Ronco M, Drozdowskyj A, Queralt C, de Aguirre I, Ramirez JL, Sanchez JJ, Molina MA, Taron M, Paz-Ares L; Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012 Mar;13(3):239-46. doi: 10.1016/S1470-2045(11)70393-X. Epub 2012 Jan 26.</citation>
    <PMID>22285168</PMID>
  </reference>
  <reference>
    <citation>Finlay MR, Anderton M, Ashton S, Ballard P, Bethel PA, Box MR, Bradbury RH, Brown SJ, Butterworth S, Campbell A, Chorley C, Colclough N, Cross DA, Currie GS, Grist M, Hassall L, Hill GB, James D, James M, Kemmitt P, Klinowska T, Lamont G, Lamont SG, Martin N, McFarland HL, Mellor MJ, Orme JP, Perkins D, Perkins P, Richmond G, Smith P, Ward RA, Waring MJ, Whittaker D, Wells S, Wrigley GL. Discovery of a potent and selective EGFR inhibitor (AZD9291) of both sensitizing and T790M resistance mutations that spares the wild type form of the receptor. J Med Chem. 2014 Oct 23;57(20):8249-67. doi: 10.1021/jm500973a. Epub 2014 Oct 1.</citation>
    <PMID>25271963</PMID>
  </reference>
  <reference>
    <citation>Camidge DR, Pao W, Sequist LV. Acquired resistance to TKIs in solid tumours: learning from lung cancer. Nat Rev Clin Oncol. 2014 Aug;11(8):473-81. doi: 10.1038/nrclinonc.2014.104. Epub 2014 Jul 1. Review.</citation>
    <PMID>24981256</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 20, 2017</study_first_submitted>
  <study_first_submitted_qc>April 25, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 28, 2017</study_first_posted>
  <last_update_submitted>February 19, 2018</last_update_submitted>
  <last_update_submitted_qc>February 19, 2018</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 20, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>NSCLC</keyword>
  <keyword>EGFR</keyword>
  <keyword>TKI</keyword>
  <keyword>EGFRm</keyword>
  <keyword>T790M</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bevacizumab</mesh_term>
    <mesh_term>Osimertinib</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

